| 5.34 0 (0%) | 02-10 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.53 | 1-year : | 6.73 |
| Resists | First : | 5.59 | Second : | 5.76 |
| Pivot price | 5.57  |
|||
| Supports | First : | 5.3 | Second : | 4.41 |
| MAs | MA(5) : | 5.47 |
MA(20) : | 5.59 |
| MA(100) : | 5.64 |
MA(250) : | 5.04 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 0 |
D(3) : | 27.6 |
| RSI | RSI(14): 39.7 | |||
| 52-week | High : | 7.51 | Low : | 3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GBIO ] has closed above bottom band by 5.8%. Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.35 - 5.38 | 5.38 - 5.4 |
| Low: | 5.27 - 5.3 | 5.3 - 5.33 |
| Close: | 5.29 - 5.34 | 5.34 - 5.39 |
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.
Thu, 21 May 2026
Generation Bio Co stock (US37148B1061): Eli Lilly deal fuels fresh attention on DNA-delivery special - AD HOC NEWS
Tue, 10 Feb 2026
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
Mon, 09 Feb 2026
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. - GlobeNewswire
Mon, 09 Feb 2026
Merger cashes out Generation Bio (GBIO) shares and cancels stock options - Stock Titan
Mon, 09 Feb 2026
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
Mon, 09 Feb 2026
XOMA Royalty acquires Generation Bio (NASDAQ: GBIO) in cash and CVR buyout - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 4.19e+006 (%) |
| Held by Institutions | 14.2 (%) |
| Shares Short | 48 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.638e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 19.9 % |
| Return on Equity (ttm) | -27.4 % |
| Qtrly Rev. Growth | 1.527e+007 % |
| Gross Profit (p.s.) | -39.26 |
| Sales Per Share | -40.21 |
| EBITDA (p.s.) | -1.61194e+007 |
| Qtrly Earnings Growth | -9.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 1.42 |
| Dividend | 0 |
| Forward Dividend | 2070 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|